BioTelemetry (BEAT) : 1492 Capital Management reduced its stake in BioTelemetry by 7.86% during the most recent quarter end. The investment management company now holds a total of 296,477 shares of BioTelemetry which is valued at $4.4 Million after selling 25,284 shares in BioTelemetry , the firm said in a disclosure report filed with the SEC on May 11, 2016.BioTelemetry makes up approximately 3.82% of 1492 Capital Management’s portfolio.
Other Hedge Funds, Including , White Pine Capital added BEAT to its portfolio by purchasing 42,275 company shares during the most recent quarter which is valued at $633,702. BioTelemetry makes up approx 0.27% of White Pine Capital’s portfolio. Hillsdale Investment Management sold out all of its stake in BEAT during the most recent quarter. The investment firm sold 19,900 shares of BEAT which is valued $298,301. Campbell Co Investment Adviser added BEAT to its portfolio by purchasing 12,210 company shares during the most recent quarter which is valued at $184,493. BioTelemetry makes up approx 0.67% of Campbell Co Investment Adviser’s portfolio.
BioTelemetry opened for trading at $14.96 and hit $15.32 on the upside on Monday, eventually ending the session at $15.31, with a gain of 2.13% or 0.32 points. The heightened volatility saw the trading volume jump to 4,89,017 shares. Company has a market cap of $427 M.
On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.10. The company had revenue of $48.60 million for the quarter, compared to analysts expectations of $46.54 million. The company’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.